The number of patients living with end-stage heart failure is steadily growing. Although
originally intended to serve solely as a bridge to more definitive surgical therapies,
there is an increasing number of patients receiving inotropic therapy (milrinone,
dobutamine) for purely palliative purposes. Continuous infusion may increase quality
of life and reduce symptom burden at the cost of increasing mortality.
To read this article in full you will need to make a payment
© 2022 Published by Elsevier Inc.